LQDA Liquidia Corporation

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The live webcast will be available on Liquidia's website at . A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350



Media:

Patrick Wallace

Director, Corporate Communications

919.328.4383



EN
12/03/2025

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports Second Quarter 2025 Financial Results and...

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovativ...

4h / 45m 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Report Second Quarter 2025 Financial Results o...

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at . A rebroadcast of the ...

August 5, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following...

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation’s request for a preli...

June 23, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostini...

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today anno...

June 2, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcar...

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.Access to a webcast will be available to ...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch